Leading the Way in AI Healthcare Innovation

As the global population ages, life-impacting chronic disease continues to escalate with significant social, economic, and healthcare consequences.

Vision impairment.

When we age, we are at increased risk of developing conditions such as diabetic retinopathy (for diabetics), glaucoma, and age-related macular degeneration (AMD). In 2020, these diseases collectively caused over 19 million cases of moderate or worse vision impairment in adults aged 50 and over, with a global financial burden estimated at US$ 411 billion annually.1

The impact on quality of life is profound. Vision impairment can affect a person’s social interactions, independence, education, emotional well-being, mobility, safety, access to information and ability to work. Individuals with vision impairment face a 30.2% relative reduction in employment.2

Cardiovascular disease (CVD).

One of the most common chronic conditions linked with ageing is CVD. As we age, our risk of heart-related conditions like coronary artery disease, heart failure, and hypertension increases, leading to an elevated risk of heart attacks, strokes, and other cardiovascular events.

People with vision impairment also exhibit an increased risk of cardiovascular disease. For example, in adults with eye diseases, there is a 39% prevalence of heart disease.3 In 2015, CVD affected an estimated 422.7 million people and caused 17.9 million deaths worldwide, accounting for 31% of global deaths.4

The solution

Optain envisions a future where everyone can access early detection of chronic disease.

That vision fuels our pioneering work in AI-powered oculomics and has produced a fast, non-invasive retinal screening platform that can spot glaucoma, diabetic retinopathy, age-related macular degeneration, and cardiovascular disease.

Accuracy, affordability, and reliability—without compromise.

By delivering precise results at the point of care, we help clinicians act sooner, safeguard patient quality of life, and run their practices more efficiently.

Artery Vein Segmentation AI Retinal Imaging

Team

Optain is a global medical device and software company. Our roots can be traced back to the Australian-founded company Eyetelligence, which was launched in 2019. Our AI retinal screening technology is the result of over a decade of research conducted by Professor Mingguang He, a leading researcher at the University of Melbourne and Centre for Eye Research in Australia.

Alejandra Maciel

Director of Clinical Affairs

Emilia Gonzalez

Director of QA/RA

Alex Crich

Director of Strategy and Operations

Babak Asgari

Director of Business Development

Charles Sweitzer

VP of Product

Jason Sun

Co-Founder and Advisor

Jeff Dunkel

Chief Executive Officer

Mingguang He MD, PhD

Co-Founder and Chief Medical Officer

Rainer Grote

SV President, International Business Development

Wei Meng

Chief Technology Officer

Dr. Zachary Tan

President, Optain Health

Zongyuan Ge PhD

Research Scientific Advisor

Tim Zoch

Director Global Operations

Nathan Young

VP Customer Success & Strategic Engagement

John David McCullough

SVP of Strategic Development

*Eyetelligence Pty Ltd, a fully owned subsidiary of Optain Health, is the legal manufacturer of Assure suite of products

References.

  1. World Health Organization. Blindness and vision impairment. Published August 10, 2023. Accessed June 5, 2025. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment  
  2. Burton MJ, Ramke J, Marques AP, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9:e489-e551. doi:10.1016/S2214-109X(20)30488-5  
  3. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25. doi:10.1016/j.jacc.2017.04.052 
  4. Mozaffarian D. Global scourge of cardiovascular disease: time for health care systems reform and precision population health. J Am Coll Cardiol. 2017;70(1):26-28. doi:10.1016/j.jacc.2017.05.007